Sana Biotechnology, Inc. (NASDAQ: SANA) is focused on creating and delivering engineered cells as medicine for patients. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and changes how we approach treating disease.
Status: Public
Beam Therapeutics
Beam Therapeutics (NASDAQ: BEAM) is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time.
Tempest Therapeutics
Tempest Therapeutics (Nasdaq: TPST) is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.
Cytek Biosciences
Cytek Biosciences Inc. (NASDAQ: CTBK) is a leading flow cytometry solution provider that provides compact, affordable instruments with high multiplexing capabilities.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, at the level of C3, the central protein in the complement cascade.
Checkmate Pharmaceuticals
Checkmate Pharmaceuticals (NASDAQ: CMPI) is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. Checkmate Pharmaceuticals was acquired by Regeneron (NASDAQ: REGH) in 2022.
Turnstone Biologics
Turnstone Biologics (NASDAQ: TSBX) is transforming patient care with a new class of targeted viral immunotherapies to fight cancer.
Medbanks
Medbanks (0314: HK) is building a data service platform for oncologists and cancer care centers in China.
VYNE Therapeutics
VYNE Therapeutics (NASDAQ: MNLO) is a late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. Formerly Menlo Therapeutics.
Xilio Therapeutics
Xilio Therapeutics (NASDAQ: XLO) is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor.